“There is no higher priority than patient health for Johnson & Johnson. Since January, we have been deeply engaged in a multipronged response to the coronavirus outbreak, leveraging proven vaccine technology that we also used to develop and manufacture our Ebola vaccine and construct our Zika, RSV, and HIV vaccines candidates. We have been working collaboratively with governments, global health organizations, academics and others and are moving at an unprecedented pace. We hope to start a Phase 1 clinical study by the end of the year, compared to the typical 5-7 years it takes for this milestone in vaccine development. We will continue to lead on this important research in support of everyone impacted by the disease,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.
